Candel Therapeutics' enLIGHTEN Discovery Platform Aims to Tackle Complexities of Tumor Microenvironments

Candel Therapeutics, Inc. (NASDAQ: CADL) is pioneering the next generation of viral immunotherapy with its enLIGHTEN Discovery Platform, integrating AI-selected therapeutic payloads into programmable vectors for delivery into the tumor microenvironment. The platform uses large patient datasets to identify druggable properties and predict optimal therapeutic payload combinations, resulting in novel bespoke immunotherapies tailored for specific indications. The company recently presented preclinical data on two experimental immunotherapy candidates at key industry conferences, demonstrating significant potential in inhibiting tumor growth and inducing therapeutic TLS formation in solid tumors. Candel is also collaborating with the University of Pennsylvania to explore the potential of its viral immunotherapies to enhance CAR T-cell therapies in solid tumor models.